Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma

Apmis ◽  
2017 ◽  
Vol 126 (1) ◽  
pp. 45-55 ◽  
Author(s):  
Bharat Rekhi ◽  
Kedar K. Deodhar ◽  
Santosh Menon ◽  
Amita Maheshwari ◽  
Jyoti Bajpai ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Serous Carcinoma ◽  
High Grade ◽  
Immunohistochemical Markers ◽  
Napsin A ◽  
Carcinoma Ovary

scholarly journals Systematic Identification of Characteristic Genes of Ovarian Clear Cell Carcinoma Compared with High-Grade Serous Carcinoma Based on RNA-Sequencing

2019 ◽  
Vol 20 (18) ◽  
pp. 4330 ◽  
Author(s):  
Saya Nagasawa ◽  
Kazuhiro Ikeda ◽  
Kuniko Horie-Inoue ◽  
Sho Sato ◽  
Atsuo Itakura ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Carcinoma ◽  
Rna Sequencing ◽  
Functional Annotation ◽  
Molecular Mechanisms ◽  
Clear Cell ◽  
Sequence Data ◽  
Clear Cell Carcinoma ◽  
Serous Carcinoma ◽  
High Grade

Objective: Ovarian cancer has the highest mortality among gynecological cancers. High-grade serous carcinoma (HGSC) is the most common histotype of ovarian cancer regardless of ethnicity, whereas clear cell carcinoma (CCC) is more common in East Asians than Caucasians. The elucidation of predominant signaling pathways in these cancers is the first step towards understanding their molecular mechanisms and developing their clinical management. Methods: RNA sequencing was performed for 27 clinical ovarian specimens from Japanese women. Principal component analysis (PCA) was conducted on the sequence data mapped on RefSeq with normalized read counts, and functional annotation analysis was performed on genes with substantial weights in PCA. Knockdown experiments were conducted on the selected genes on the basis of PCA. Results: Functional annotation analysis of PCA-defined genes showed predominant pathways, such as cell growth regulators and blood coagulators in CCC and transcription regulators in HGSC. Knockdown experiments showed that the inhibition of the calcium-dependent protein copine 8 (CPNE8) and the transcription factor basic helix-loop-helix family member e 41 (BHLHE41) repressed the proliferation of CCC- and HGSC-derived cells, respectively. Conclusions: This study identified CPNE8 and BHLHE41 as characteristic genes for CCC and HGSC, respectively. The systemic identification of differentially expressed genes in CCC and HGSC will provide useful information to understand transcriptomic differences in these ovarian cancers and to further develop potential diagnostic and therapeutic options for advanced disease.

Establishment of Patient-Derived Tumor Xenograft Models of High-Risk Endometrial Cancer

2018 ◽  
Vol 28 (9) ◽  
pp. 1812-1820 ◽  
Author(s):  
Menghan Zhu ◽  
Nan Jia ◽  
Yanyan Nie ◽  
Jun Chen ◽  
Yahui Jiang ◽  
...  
Keyword(s):  
High Risk ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Tumor Xenograft ◽  
Serous Carcinoma ◽  
High Grade ◽  
Primary Tumors ◽  
P53 Expression ◽  
Subrenal Capsule

ObjectiveHigh-risk endometrial cancers (ECs), including high-grade EC, serous carcinoma (SC), clear cell carcinoma, and carcinosarcoma, account for 50% of deaths due to ECs. Therapies for these cancers are limited, and patient-derived tumor xenograft (PDTX) models are useful tools for preclinical drug evaluation, biomarker identification, and personalized medicine strategies. Here, we used and compared 2 methods to establish PDTX models.MethodsFresh tumor tissues collected from 18 primary high-risk EC patients (10 high-grade ECs, 6 SCs, 1 clear cell carcinoma, and 1 carcinosarcoma) were engrafted subcutaneously and in the subrenal capsule in NOD/SCID for establishment and Balb/c-nu/nu mice for expansion. Histology and cytokeratin, estrogen receptor, progesterone receptor, and P53 expression were evaluated to assess the similarity of primary tumors and different generations of PDTX tumors. Whole-exome sequencing (WES) and RNA sequencing were used in 2 high-grade EC models to verify whether the genetic mutation profiles and gene expression were similar between primary and PDTX tumors.ResultsThe total tumor engraftment rate was 77.8% (14/18) regardless of the engraft method. The tumor engraftment rate was increased in subrenal capsule models compared with subcutaneous models (62.5% vs 50%, P = 0.464). The time to tumor formation varied significantly from 2 to 11 weeks. After subrenal capsular grafting, grafted tumors could be successfully transplanted to subcutaneous sites. We observed good similarity between primary tumors and corresponding different passages of xenografts.ConclusionsThe combination of 2 engrafting methods increases the tumor engraftment rate. The high tumor engraftment rate ensures the establishment of a high-risk EC biobank, which is a powerful resource for performing preclinical drug-sensitivity tests and identifying biomarkers for response or resistance.

The Analysis of Cell Cycle–related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma

2018 ◽  
Vol 37 (6) ◽  
pp. 516-524 ◽  
Author(s):  
Yukiko Hazama ◽  
Takuya Moriya ◽  
Mika Sugihara ◽  
Rikiya Sano ◽  
Mitsuru Shiota ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Serous Carcinoma ◽  
High Grade ◽  
Ovarian Clear Cell Carcinoma ◽  
Related Proteins

Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas

2018 ◽  
Vol 28 (7) ◽  
pp. 1318-1324 ◽  
Author(s):  
Eirwen M. Miller ◽  
Joan Tymon-Rosario ◽  
Jaya Sunkara ◽  
Bryan E. Harmon ◽  
Rouzan G. Karabakhtsian ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Medical Center ◽  
Diagnostic Tools ◽  
High Grade ◽  
Napsin A ◽  
Treatment Data ◽  
Endometrial Cancers ◽  
Immunohistochemical Profile

ObjectiveDiagnosis of endometrial clear cell carcinomas is difficult owing to the low reproducibility of histological cell type in high-grade endometrial cancers. Recently, immunoreactivity for napsin A and glypican 3 has been reported in clear cell cancers. We sought to evaluate the use of napsin A and glypican 3 staining to distinguish clear cell carcinoma from other high-grade endometrial cancers.Methods/MaterialsTwenty cases of pure and mixed endometrial clear cell carcinoma were extracted from the 2000–2014 archival material in the Departments of Obstetrics & Gynecology and Pathology at Montefiore Medical Center and compared to serous and grade 3 endometrioid controls. Representative sections were stained with monoclonal antibodies to napsin A and glypican 3. Immunostains were independently reviewed by 2 pathologists to assess frequency and pattern of staining. Charts were reviewed for clinicopathologic and treatment data.ResultsGranular cytoplasmic positivity for napsin A was observed in 70% of endometrial clear cell carcinomas; only 25% showed cytoplasmic or membranous glypican 3 positivity. No serous or high-grade endometrioid tumors stained for either marker. No cases of clear cell carcinoma that stained negative for napsin A stained positive for glypican 3. No difference in the immunohistochemical profile was found between pure and mixed clear cell carcinomas and between early- and advanced-stage clear cell carcinomas.ConclusionsNapsin A is a more sensitive marker for endometrial clear cell carcinoma than glypican 3. In histologically ambiguous cases, napsin A and glypican 3 may help distinguish clear cell carcinoma from other high-grade histologies. Further investigation of endometrial clear cell carcinoma is needed to identify additional diagnostic tools for this rare histology. Correlation of a unique immunohistochemical profile and clinical outcomes is necessary.

scholarly journals Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma

Brachytherapy ◽  
2019 ◽  
Vol 18 (1) ◽  
pp. 38-43 ◽  
Author(s):  
Minsi Zhang ◽  
T. Jonathan Yang ◽  
Neil B. Desai ◽  
Deborah DeLair ◽  
Marisa A. Kollmeier ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Serous Carcinoma ◽  
Uterine Clear Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document